首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Impact of Dose De-Escalation and Escalation on Daptomycins Pharmacodynamics against Clinical Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Model
【2h】

Impact of Dose De-Escalation and Escalation on Daptomycins Pharmacodynamics against Clinical Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Model

机译:剂量递减和递增对达托霉素在体外模型中抗耐甲氧西林金黄色葡萄球菌临床药理作用的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

De-escalation and escalation therapeutic strategies are commonly employed by clinicians on the basis of susceptibility results and patient response. Since no in vitro or in vivo data are currently available to support one strategy over the other for daptomycin, we attempted to evaluate the effects of dose escalation and de-escalation on daptomycin activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates using an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations. Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ∼109 CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin MIC values ranged from 0.5 to 1 μg/ml. In the PK/PD model, high-dose daptomycin (10 mg/kg/day) and de-escalation simulation (10 to 6 mg/kg/day) appeared to be the most efficient regimens against the three tested isolates, exhibiting the fastest bactericidal activity (4 to 8 h) compared to that of the standard regimen of 6 mg/kg/day and the escalation therapy of 6 to 10 mg/kg/day. The differences in the numbers of CFU/g observed between dose escalation and de-escalation were significant for the hVISA strain, with the de-escalation simulation exhibiting a better killing effect than the escalation simulation (P < 0.024). Although our results need to be carefully considered, the use of high-dose daptomycin up front demonstrated the most efficient activity against the tested isolates. Different therapeutic scenarios including isolates with higher MICs and prolonged drug exposures are warranted to better understand the outcomes of escalation and de-escalation strategies.
机译:临床医师通常根据药敏结果和患者反应采用降级和升级治疗策略。由于目前尚无用于达托霉素的体外或体内数据来支持另一种策略,因此,我们尝试使用inc来评估剂量升高和降级对达托霉素针对耐甲氧西林金黄色葡萄球菌(MRSA)分离物的活性的影响。具有模拟心内膜植被的体外药代动力学/药效学(PK / PD)模型。将三种临床MRSA分离物(包括一种异质的万古霉素中间金黄色葡萄球菌(hVISA)分离物和一种万古霉素中性金黄色葡萄球菌(VISA)分离物)以10或6 mg / kg体重/天的剂量暴露于达托霉素8天使用约10 9 CFU / g植被的起始接种物,在第四天开始剂量递增和降级。达托霉素的MIC值范围为0.5至1μg/ ml。在PK / PD模型中,大剂量达托霉素(10 mg / kg /天)和降级模拟(10至6 mg / kg /天)似乎是针对三种测试菌株的最有效方案,表现出最快的与标准方案6 mg / kg / day和逐步升级疗法6-10 mg / kg / day相比,其杀菌活性(4至8小时)。对于hVISA菌株,剂量递增和递减之间观察到的CFU / g数目的差异是显着的,与递增递增模拟相比,递减递增模拟显示出更好的杀灭效果(P <0.024)。尽管我们的结果需要仔细考虑,但预先使用大剂量达托霉素显示出对被测菌株最有效的活性。为了更好地了解逐步升级和逐步降低策略的结果,有必要采用不同的治疗方案,包括具有较高MIC的分离株和延长的药物暴露时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号